Program
Epinephrine
Also written as “epinephrine inhalation aerosol”, “Epinephrine Nasal Spray, 2.5 mg” and “Epinephrine Nasal Spray, 5.25 mg”.
Its studies are mostly in Anaphylaxis · Asthma · Hypersensitivity · Chronic Urticaria · Respiratory Tract Infections, led by 7 companies.
Drug pageEpinephrine: every studyMany companies study it; this page follows only the 16 they lead. All 221 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amphastar Pharmaceuticalsits history only | 40 open or running | phase 4since Dec 19, 2019 | Jun 7, 2010 | none ahead |
| Nasus Pharmaits history only | 42 open or running | phase 3since Jun 8, 2025 | Dec 1, 2020 | none ahead |
| ARS Pharmaceuticals | 32 open or running | phase 4since Feb 18, 2025 | Jun 9, 2021 | Apr 2027phase 4 · NCT06834165 |
| De Motu Cordisits history only | 20 open or running | phase 1since Nov 9, 2021 | Nov 9, 2021 | none ahead |
| ALK-Abellóits history only | 10 open or running | phase 4since Jun 20, 2013 | Jun 20, 2013 | none ahead |
| Hikma Pharmaceuticalsits history only | 11 open or running | phase 2since Aug 18, 2026 | Aug 18, 2026 | May 8, 2027phase 2 · NCT07891780 |
| Smith & Nephewits history only | 10 open or running | phase 2since Apr 5, 2017 | Apr 5, 2017 | none ahead |
Also a collaborator on its studies: Medistat Ltd., Israel, Pharma Medica Research and Novotech (Australia) Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ARS Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2021First study: phase 1 study in Respiratory Tract InfectionsFirst studyNCT04930900 · 15 enrolled · Australia
- Feb 18, 2025Phase 4 study in HypersensitivityNCT06834165 · 600 planned · United States
- Apr 4, 2025Phase 2 study in Chronic UrticariaNCT06927999 · 42 planned · United States, Germany
Ahead
- Apr 2027Primary completion: phase 4 study in HypersensitivityNCT06834165
- Jun 2027Primary completion: phase 2 study in Chronic UrticariaNCT06927999
TargetBeta
“Adrenergic receptor agonist; Adrenergic receptor agonist”ChEMBL 37, by rule
Studies
All 3 ARS Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06927999Chronic Urticaria · United States, Germany | 2 | Recruiting | Jun 2027 | 42 |
| NCT06834165Hypersensitivity · United States | 4 | Recruiting | Apr 2027 | 600 |
| NCT04930900Respiratory Tract Infections · Australia | 1 | Completed | Mar 31, 2022 | 15 |
How it is read
Names in the registry
- “epinephrine inhalation aerosol”, 4 entries
- “Epinephrine Nasal Spray, 2.5 mg”, 1 entry
- “Epinephrine Nasal Spray, 5.25 mg”, 1 entry
- “0.5 mg epinephrine”, 1 entry
- “1 mg epinephrine”, 1 entry
Codes read as this program: FMXIN002.
Conditions, from the studies’ own filings
- Anaphylaxis, 7 studies
- Asthma, 4 studies
- Hypersensitivity, 2 studies
- Chronic Urticaria, 1 study
- Respiratory Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.